Government-Owned Inventions; Availability for Licensing, 53743 [2019-21965]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 195 / Tuesday, October 8, 2019 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
jbell on DSK3GLQ082PROD with NOTICES
Licensing information and copies of the
U.S. patent application listed below
may be obtained by communicating
with Sury Vepa, Ph.D., J.D., Senior
Licensing and Patenting Manager,
National Center for Advancing
Translational Sciences, NIH, 9800
Medical Center Drive, Rockville, MD
20850, Phone: 301–827–7181, or email
sury.vepa@nih.gov. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Inhibitors of Phosphoinositide 3-Kinase
and Histone Deacetylase for Treatment
of Cancer
Description of Technology: The
invention includes compounds that act
as dual inhibitor of phosphoinositide 3kinase (PI3K) and histone deacetylase
(HDAC), including a core containing a
quinazoline moiety or a quinazolin4(3H)-one moiety, a kinase hinge
binding moiety, and a histone
deacetylase pharmacophore, a
pharmaceutically acceptable salt
thereof, a prodrug thereof, or solvate
thereof. The present invention also
provides compounds that are selective
inhibitors of histone deacetylase
inhibitor that include a core containing
a quinazolin-4(3H)-one moiety and a
histone deacetylase pharmacophore.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Novel therapeutics for cancers
neurodegenerative diseases.
Competitive Advantages:
• Novel dual inhibitor compounds of
this invention have a commercial
advantage over those currently known
VerDate Sep<11>2014
21:50 Oct 07, 2019
Jkt 250001
because they can act as selective and
dual inhibitors of specific isoforms of
HDAC (such as HDAC6) and PI3K (such
as PI3Kd) potentially providing better
toxicity profile and therefore bigger
therapeutic window.
Development Stage:
• Pre-Clinical (compound
optimization and in vivo validation).
Inventors:
• Grewal, Gurmit; Thakur, Ashish;
Tawa, Gregory James; Ferrer, Marc; and
Simeonov, Anton M.
Intellectual Property: 1. INHIBITORS
OF PHOSPHOINOSITIDE 3–KINASE
AND HISTONE DEACETYLASE FOR
TREATMENT OF CANCER, PCT Patent
Application NO. PCT/US2018/038507
filed on June 20, 2018 (HHS Ref. No. E–
104–2017).
Licensing Contact: Sury Vepa, Ph.D.,
J.D. Phone: 301–827–7181, or email
sury.vepa@nih.gov.
Dated: October 1, 2019.
Lillianne M. Portilla Weingarten,
Technology Development Coordinator,
National Center for Advancing Translational
Sciences.
[FR Doc. 2019–21965 Filed 10–7–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; Drug Screening with Bio
Fabricated 3–D Skin Disease Tissue Models.
Date: October 23, 2019.
Time: 2:00 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
53743
Contact Person: Rahat (Rani) Khan, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Center for Advancing,
Translational Sciences, 6701 Democracy
Blvd., Rm 1078, Bethesda, MD 20892, 301–
894–7319, khanr2@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: October 2, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–21851 Filed 10–7–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Amended Notice of
Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
Child Health and Human Development
Special Emphasis Panel on Pediatric
Trauma and Injury Prevention, which
was published in the Federal Register
on September 25, 2019, 84 FR 50460.
This meeting’s location and format
has changed from an in-person meeting
at the Residence Inn, Bethesda MD to an
IAT/Teleconference meeting at 6710B
Rockledge Dr., Bethesda MD. The
meeting is closed to the public.
Dated: October 2, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–21850 Filed 10–7–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
E:\FR\FM\08OCN1.SGM
08OCN1
]]>Agencies
[Federal Register Volume 84, Number 195 (Tuesday, October 8, 2019)]
[Notices]
[Page 53743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21965]
[[Page 53743]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent application listed below may be obtained by
communicating with Sury Vepa, Ph.D., J.D., Senior Licensing and
Patenting Manager, National Center for Advancing Translational
Sciences, NIH, 9800 Medical Center Drive, Rockville, MD 20850, Phone:
301-827-7181, or email [email protected]. A signed Confidential
Disclosure Agreement will be required to receive copies of unpublished
patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Inhibitors of Phosphoinositide 3-Kinase and Histone Deacetylase for
Treatment of Cancer
Description of Technology: The invention includes compounds that
act as dual inhibitor of phosphoinositide 3-kinase (PI3K) and histone
deacetylase (HDAC), including a core containing a quinazoline moiety or
a quinazolin-4(3H)-one moiety, a kinase hinge binding moiety, and a
histone deacetylase pharmacophore, a pharmaceutically acceptable salt
thereof, a prodrug thereof, or solvate thereof. The present invention
also provides compounds that are selective inhibitors of histone
deacetylase inhibitor that include a core containing a quinazolin-
4(3H)-one moiety and a histone deacetylase pharmacophore.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Novel therapeutics for cancers neurodegenerative diseases.
Competitive Advantages:
Novel dual inhibitor compounds of this invention have a
commercial advantage over those currently known because they can act as
selective and dual inhibitors of specific isoforms of HDAC (such as
HDAC6) and PI3K (such as PI3K[delta]) potentially providing better
toxicity profile and therefore bigger therapeutic window.
Development Stage:
Pre-Clinical (compound optimization and in vivo
validation).
Inventors:
Grewal, Gurmit; Thakur, Ashish; Tawa, Gregory James;
Ferrer, Marc; and Simeonov, Anton M.
Intellectual Property: 1. INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE
AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER, PCT Patent Application
NO. PCT/US2018/038507 filed on June 20, 2018 (HHS Ref. No. E-104-2017).
Licensing Contact: Sury Vepa, Ph.D., J.D. Phone: 301-827-7181, or
email [email protected].
Dated: October 1, 2019.
Lillianne M. Portilla Weingarten,
Technology Development Coordinator, National Center for Advancing
Translational Sciences.
[FR Doc. 2019-21965 Filed 10-7-19; 8:45 am]
BILLING CODE 4140-01-P
